Opus Genetics
IRD
41 hedge funds and large institutions have $6.69M invested in Opus Genetics in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 8 closing their positions.
201% more call options, than puts
Call options by funds: $238K | Put options by funds: $79K
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
3% more funds holding
Funds holding: 40 → 41 (+1)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
1.65% less ownership
Funds ownership: 12.54% → 10.9% (-1.6%)
17% less capital invested
Capital invested by funds: $8.07M → $6.69M (-$1.38M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RB
Richmond Brothers
Jackson,
Michigan
|
+$172K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$133K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$102K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$53.4K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$47.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$245K |
| 2 |
Two Sigma Investments
New York
|
-$233K |
| 3 |
Millennium Management
New York
|
-$177K |
| 4 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$130K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$82.9K |
IRD Hedge Fund Activity: Q1 2022 in Review
41 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q1 2022, worth a combined $6.69M — down 17% from $8.07M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new IRD positions and 8 closed out — a net gain of 2 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Richmond Brothers, adding an estimated $172K. The largest seller was Two Sigma Advisers, cutting an estimated $245K.
- 41 institutional investors held Opus Genetics (IRD) as of Q1 2022, up from 40 in Q4 2021.
- Funds reported $6.69M of Opus Genetics stock for Q1 2022, down 17% quarter-over-quarter.
- 10 funds opened new Opus Genetics positions in Q1 2022 and 8 closed out, a net change of +2 holders.
- The largest Opus Genetics buyer in Q1 2022 was Richmond Brothers, an estimated $172K added.
- The largest Opus Genetics seller in Q1 2022 was Two Sigma Advisers, an estimated $245K sold.
Based on aggregated 13F filings for Q1 2022.